The addition of pembrolizumab to modern and high-quality chemoradiotherapy significantly improved overall survival (OS) in patients with locally advanced cervical cancer, according to results from the phase 3 KEYNOTE-A18 study. In recent years, modern, high-quality radiotherapy has increased local control and OS, as well as reduced toxicity of the treatment...